🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Singapore / NCT06757296
Recruiting Not applicable

Endoscopic Conversion of Sleeve Gastrectomy to Single Anastomosis Sleeve-ileal Bypass (SASI) for Gastroesophageal Reflux (GERD), Primary and Secondary Non-responder.

NCT06757296 · tracked via the Priya Life Science Singapore tracker
Sponsor
Singapore Health Services
Phase
Not applicable
Started
2025-02-03
Last updated
2025-02-14

Condition(s) studied

Metabolic SyndromeSevere ObesityReflux, GastroesophagealBariatric Surgery

Investigational drug(s) / intervention(s)

Endoscopic SASI

Endoscopic SASI: Endoscopic conversion to sleeve gastrectomy to SASI

Study summary

The aim of this study is to determine the feasibility and effectiveness of endoscopic anastomosis of sleeve gastrectomy to ileum with a lumen apposing metal stent (LAMS) after a failed sleeve gastrectomy.

Eligibility

Sex
ALL
Min age
21 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: Subject must meet all the inclusion criteria to participate in this study and list each criterion. 1. Age: 21-65 years 2. Patients going for LSG at participating hospitals. 3. Able to provide informed consent Individuals below age 21 would not be recruited as this is a study in the adult population. Individuals above age 65 are excluded to minimize the procedure risk. Exclusion Criteria: 1. Patients who were breast feeding or pregnant 2. Severe psychiatric illness 3. Eating disorder 4. Active neoplastic disease 5. End-stage renal disease 6. Patients with bleeding diathesis 7. Patients with pacemakers or implantable cardiac defibrillators 8. Significant cardiovascular disease (e.g., acute myocardial infarction, congestive cardiac failure, ischemic heart disease, atrial fibrillation, sick sinus syndrome, supraventricular tachycardia) 9. Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other or family members) 10. Treatment with anti-platelet agents that could not be temporarily discontinued

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Changi General Hospital Singapore Singapore Recruiting
Sengkang General Hospital Singapore Singapore Recruiting
Singapore General Hospital Singapore Singapore Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06757296 on ClinicalTrials.gov ↗ ← All trials in Singapore